View ValuationPegBio 将来の成長Future 基準チェック /06現在、 PegBioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長32.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Aug 13PegBio Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026PegBio Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Revenue is less than US$1m.お知らせ • Jun 25Pegbio Co., Ltd. Announces Appointment of Yik Lam Liao as Non-Executive Director and Chairperson of the Audit Committee and A Member of Each of the Remuneration and Appraisal Committee and the Nomination Committee, Effective June 24, 2026PegBio Co., Ltd. held its annual general meeting on June 24, 2026. Upon approval at the AGM, Ms. Yik Lam LIAO was appointed as an independent non-executive Director of the second session of the Board, for a term up to the expiration of the second session of the Board commencing from June 24, 2026. Ms. LIAO will serve as the chairperson of the Audit Committee and a member of each of the Remuneration and Appraisal Committee and the Nomination Committee, with a term of office consistent with her term as an independent non-executive Director of the second session of the Board. The biographical details of Ms. LIAO and the information required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there have been no changes to such information.お知らせ • Jun 02PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026, at 10:00 China Standard Time. Location: 6/f, block a, no. 520 shaoxing road, gongshu district, zhejiang province, hangzhou ChinaNew Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥66m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change).お知らせ • Mar 11PegBio Co., Ltd. to Report Fiscal Year 2025 Results on Mar 23, 2026PegBio Co., Ltd. announced that they will report fiscal year 2025 results on Mar 23, 2026Board Change • Feb 03Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 23PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million.PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 5,136,000 Price\Range: HKD 58.41 Transaction Features: Subsequent Direct Listingお知らせ • Aug 15PegBio Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025PegBio Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥185m free cash flow). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 26PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million.PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 9,642,000 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Security Name: H Shares Security Type: Common Stock Securities Offered: 57,000 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Security Name: H Shares Security Type: Common Stock Securities Offered: 9,584,500 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Transaction Features: Regulation S; Sponsor Backed Offering このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PegBio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測SEHK:2565 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025N/A-208-156-152N/A9/30/2025N/A-215-156-154N/A6/30/2025N/A-221-156-155N/A3/31/2025N/A-252-170-169N/A12/31/2024N/A-283-185-183N/A12/31/2023N/A-279-208-233N/A12/31/2020N/A-130-189-189N/A12/31/20190-207-69-68N/A12/31/20180-91N/A-61N/Aアナリストによる今後の成長予測収入対貯蓄率: 2565の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2565の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2565の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2565の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2565の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2565の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 09:53終値2026/08/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PegBio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 13PegBio Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026PegBio Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Revenue is less than US$1m.
お知らせ • Jun 25Pegbio Co., Ltd. Announces Appointment of Yik Lam Liao as Non-Executive Director and Chairperson of the Audit Committee and A Member of Each of the Remuneration and Appraisal Committee and the Nomination Committee, Effective June 24, 2026PegBio Co., Ltd. held its annual general meeting on June 24, 2026. Upon approval at the AGM, Ms. Yik Lam LIAO was appointed as an independent non-executive Director of the second session of the Board, for a term up to the expiration of the second session of the Board commencing from June 24, 2026. Ms. LIAO will serve as the chairperson of the Audit Committee and a member of each of the Remuneration and Appraisal Committee and the Nomination Committee, with a term of office consistent with her term as an independent non-executive Director of the second session of the Board. The biographical details of Ms. LIAO and the information required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there have been no changes to such information.
お知らせ • Jun 02PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026, at 10:00 China Standard Time. Location: 6/f, block a, no. 520 shaoxing road, gongshu district, zhejiang province, hangzhou China
New Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥66m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change).
お知らせ • Mar 11PegBio Co., Ltd. to Report Fiscal Year 2025 Results on Mar 23, 2026PegBio Co., Ltd. announced that they will report fiscal year 2025 results on Mar 23, 2026
Board Change • Feb 03Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 23PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million.PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 5,136,000 Price\Range: HKD 58.41 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 15PegBio Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025PegBio Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥185m free cash flow). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 26PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million.PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million. Security Name: H Shares Security Type: Common Stock Securities Offered: 9,642,000 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Security Name: H Shares Security Type: Common Stock Securities Offered: 57,000 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Security Name: H Shares Security Type: Common Stock Securities Offered: 9,584,500 Price\Range: HKD 15.6 Discount Per Security: HKD 0.78 Transaction Features: Regulation S; Sponsor Backed Offering